The effect of hormone replacement therapy and simvastatin on plasma homocysteine

Journal of Women's Health

Volumn 14, Issue 2, 2005, Pages 154-158

  Sbarouni, Eftihia ^a   Kyriakides, Zenon S ^a   Kremastinos, Dimitrios Th ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CONJUGATED ESTROGEN; HOMOCYSTEINE; MEDROXYPROGESTERONE; PLACEBO; SIMVASTATIN;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG DOSE REGIMEN; DRUG MECHANISM; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; MENOPAUSE; MONOTHERAPY; POSTMENOPAUSE; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX DIFFERENCE;

AGED; ANTILIPEMIC AGENTS; CORONARY ARTERIOSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HOMOCYSTEINE; HUMANS; HYPERCHOLESTEROLEMIA; MEDROXYPROGESTERONE; MIDDLE AGED; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 17644419083     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2005.14.154     Document Type: Article

References (38)

1. Ridker PM, Manson JE, Buring JE, et al. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 1999;281:1817.
2. Davison S, Davis SR. New markers for cardiovascular disease risk in women: Impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003;88:2470.
3. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995;274: 1526.
4. Morris MS, Jacques PF, Selhub J, et al. Total homocysteine and estrogen status indicators in the third National Health and Nutrition Examination Survey. Am J Epidemiol 2000;152;140.
5. Hak AE, Polderman KH, Westendrop ICD, et al. Increased plasma homocysteine after menopause. Atherosclerosis 2000;149:163.
6. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial. J Clin Endocrinol Metab 2000;85:214.
7. Hak AE, Bak AA, Lindemans J, et al. The effect of hormone replacement therapy on serum homocysteine levels in perimenopausal women: A randomized controlled trial. Atherosclerosis 2001;158:437.
8. Lacut K, Oger E, Abalain JH, Moineau MP, Mottier D, on behalf of the SARAH investigators. Effects of oral and transdermal 17 beta-estradiol combined with progesterone on homocysteine metabolism in postmenopausal women: A randomised placebo-controlled trial. Atherosclerosis 2004;174:173.
9. Giltay EJ, Hoogeveen EK, Elbers JM, et al. Effects of sex steroids on plasma total homocysteine levels: A study in transsexual males and females. J Clin Endocrinol Metab 1998;83:550.
10. Blankenhorn DH, Malinow MR, Mack WJ. Colestopil plus niacin therapy elevates plasma homocysteine levels. Cor Arterty Dis 1991;2:357.
11. Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 1999;354:219.
12. de Lorgeril M, Salen P, Paillard F, et al. Lipid lowering drugs and homocysteine. Lancet 1999;353:209.
13. Giral P, Bruckert E, Jacob N, et al. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis 2001;154:421.
14. Dierkes J, Westphal S, Kunstmann S, et al. Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate. Atherosclerosis 2001;158:161.
15. Melenovsky V, Malik J, Wichterle D, et al. Comparison of the effects of atorvastatin or fenofibrate on non-lipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J 2002;144:E6.
16. Olszewski AJ, McCully KS. Fish oil decreases serum homocysteine in hyperlipidemic men. Cor Artery Dis 1993;4:53.
17. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 2001;104:499.
18. Sbarouni E, Kyriakides Z, Kremastinos D. The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. J Am Coll Cardiol 1998;32:1244.
19. Herrington DM, Werbel BL, Riley WA, et al. Individual and combined effects of estrogen/progestin therapy and lovostatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. J Am Coll Cardiol 1999;33:2030.
20. Wilcken D, Wang X, Adachi T, et al. Relationship between homocysteine and superoxide dismutase in homocysteinuria: Possible relevance to cardiovascular risk. Arterioscler Thromb Vasc Biol 2000;20:1199.
21. Mijatovic V, Kenemans P, Jakobs C, et al. A randomized controlled study of the effect of 17beta-estradioldydrogesterone on plasma homocysteine in postmenopausal women. Obstet Gynecol 1998;91:432.
22. Mijatovic V, Netelendos C, van der Mooren MJ, et al. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil Steril 1998;70:1085.
23. van Baal WM, Smolders RG, van der Mooren MJ, et al. Hormone replacement therapy and plasma homocysteine levels. Obstet Gynecol 1999;94:485.
24. Madsen JS, Kristensen SR, Klitgaard NA, et al. Effect of long-term hormone replacement therapy on plasma homocysteine in postmenopausal women: A randomized controlled study. Am J Obstet Gynecol 2002;187:33.
25. Chiantera V, Sarti CD, Fornaro F, et al. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels. Menopause 2003;10:286.
26. Smolders RG, van der Mooren MJ, Teerlink T, et al. A randomized placebo-controlled study of the effect of transdermal vs. oral estradiol with or without gestodene on homocysteine levels. Fertil Steril 2003;79:261.
27. Luftjohann D, Sigit JI, Locatelli S, et al. High-dose simvastatin decreases plasma concentrations of total homocysteine in patients with hypercholesterolemia. Atherosclerosis 2001;155:265.
28. Blom HJ, Boers GH, van den Elzen, JP, et al. Differences between premenopausal women and young women in the transamination pathway of methionine catabolism, and the protection against vascular disease. Eur J Clin Invest 1988;18:633.
29. Lang D, Kredan MB, Moat SJ, et al. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: Role for superoxide anions. Arterioscler Thromb Vasc Biol 2000;20:422.
30. Dimitrova KR, DeGroot KW, Suyderhood JP, et al. Estradiol prevents homocysteine-induced endothelial injury in male rats. Cardiovasc Res 2002;53:589.
31. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991;324:1149.
32. Boushey CJ, Beresford SAA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049.
33. Verhoef P, Meleady R, Daly LE, et al. Homocysteine, vitamin status and risk of vascular disease: Effects of gender and menopausal status. Eur Heart J 1999; 20:1234.
34. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998;98:204.
35. Stubbs PJ, Al-Obaidi MK, Conroy RM, et al. Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes. Circulation 2000;102:605.
36. Selhub J, Jacques PF, Rosenberg IH, et al. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey: Population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med 1999;131:331.
37. Mosca L, Appel L, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004;109:672.
38. Splaver A, Lamas GA, Hennekens CH. Homocysteine and cardiovascular disease: Biological mechanisms, observational epidemiology, and the need for randomized trials. Am Heart J 2004;148:34.